Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment-experienced patients, particularly those with cirrhosis, had suboptimal su...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hepatology
Glavni autori: Lawitz, Eric, Poordad, Fred, Brainard, Diana M, Hyland, Robert H, An, Di, Dvory-Sobol, Hadas, Symonds, William T, McHutchison, John G, Membreno, Fernando E
Format: Artigo
Jezik:Inglês
Izdano: BlackWell Publishing Ltd 2015
Teme:
Rapid Communication
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365682/
https://ncbi.nlm.nih.gov/pubmed/25322962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27567
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items